Autolus Therapeutics plc (NASDAQ: AUTL)

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune diseases using a broad suite of proprietary and modular T cell programming technologies to engineer precisely targeted and controlled T cell therapies designed to better recognize target cells break down their defense mechanisms and eliminate target cells.

Autolus Therapeutics plc generates revenue primarily through the sale of its commercial product AUCATZYL (obecabtagene autoleucel also known as obe-cel) a CD19-directed chimeric antigen receptor T cell therapy approved for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States United Kingdom and European Union with commercial launch occurring in the United States in January 2025 the United Kingdom in January 2026 and in the European Union with marketing authorization granted in July 2025 although market entry in certain EU countries remains on hold as of the filing date with no anticipated EU sales in 2026 and additional revenue potential from ongoing clinical development programs in pediatric oncology and autoimmune indications such as systemic lupus erythematosus lupus nephritis and progressive multiple sclerosis.

Autolus Therapeutics plc does not report distinct operational segments as it manages its business as a single entity focused on the development and commercialization of its T cell programming technology platform and product candidates.

Autolus Therapeutics plc competes in the chimeric antigen receptor T cell therapy market with its lead product AUCATZYL facing direct in-class competitors such as Kymriah developed by Novartis and Tecartus developed by Kite Pharma a Gilead company for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia with Autolus asserting a differentiated safety profile due to its fast off-rate CD19-binding domain designed to minimize excessive T cell activation reduce cytokine release syndrome and immune effector cell-associated neurotoxicity while aiming to improve durability of response and potentially offer curative benefit in some patients and the company believes its leadership in T cell programming technologies including pharmacological control modules safety switches and microenvironment shielding provides a competitive advantage for expanding into hematological cancers solid tumors and autoimmune diseases.

Autolus Therapeutics plc serves hospitals and specialized treatment centers that are authorized to administer chimeric antigen receptor T cell therapies including academic medical centers and oncology clinics in the United States United Kingdom and European Union where AUCATZYL is commercially available and where clinical trials for its product candidates in pediatric B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma systemic lupus erythematosus lupus nephritis and progressive multiple sclerosis are conducted.